Patents by Inventor David J. Ballance
David J. Ballance has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080269127Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encodings the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the intention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: October 29, 2007Publication date: October 30, 2008Inventors: David J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Publication number: 20080267962Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encodings the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the intention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: October 29, 2007Publication date: October 30, 2008Inventors: David J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Publication number: 20080269128Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encodings the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the intention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: October 29, 2007Publication date: October 30, 2008Inventors: David J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Publication number: 20080269126Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: October 29, 2007Publication date: October 30, 2008Inventors: David J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Publication number: 20080269125Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encodings the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the intention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: October 29, 2007Publication date: October 30, 2008Inventors: David J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Publication number: 20080261877Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encodings the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the intention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: October 29, 2007Publication date: October 23, 2008Inventors: David J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Publication number: 20080167238Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: October 30, 2007Publication date: July 10, 2008Applicants: Human Genome Sciences, Inc., Delta Biotechnology LimitedInventors: Craig A. Rosen, William A. Haseltine, David J. Ballance, Andrew J. Turner, Steven M. Ruben
-
Publication number: 20080167240Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: October 30, 2007Publication date: July 10, 2008Applicants: Human Genome Sciences, Inc., Delta Biotechnology LimitedInventors: Craig A. Rosen, William A. Haseltine, David J. Ballance, Andrew J. Turner, Steven M. Ruben
-
Publication number: 20080167239Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: October 30, 2007Publication date: July 10, 2008Applicants: Human Genome Sciences, Inc., Delta Biotechnology LimitedInventors: Craig A. Rosen, William A. Haseltine, David J. Ballance, Andrew J. Turner, Steven M. Ruben
-
Publication number: 20080161243Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: October 30, 2007Publication date: July 3, 2008Applicants: Human Genome Sciences, Inc., Delta Biotechnology LimitedInventors: Craig A. Rosen, William A. Haseltine, David J. Ballance, Andrew J. Turner, Steven M. Ruben
-
Publication number: 20080153751Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: October 30, 2007Publication date: June 26, 2008Applicants: Human Genome Sciences, Inc., Delta Biotechnology LimitedInventors: Craig A. Rosen, William A. Haseltine, David J. Ballance, Andrew J. Turner, Steven M. Ruben
-
Publication number: 20080146503Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: July 2, 2007Publication date: June 19, 2008Applicants: Human Genome Sciences, Inc., Delta Biotechnology LimitedInventors: Craig A. Rosen, William A. Haseltine, David J. Ballance, Andrew J. Turner, Steven M. Ruben
-
Publication number: 20080131399Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encodings the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the intention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: October 30, 2007Publication date: June 5, 2008Inventors: David J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Patent number: 7141547Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.Type: GrantFiled: February 11, 2004Date of Patent: November 28, 2006Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, William A. Haseltine, David J. Ballance, Andrew J. Turner, Steven M. Ruben
-
Publication number: 20030199043Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.Type: ApplicationFiled: April 12, 2001Publication date: October 23, 2003Inventors: David J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Patent number: 6290953Abstract: A method of modulating cellular proliferation by the application of a thymidine phosphorylase to an organism. In a further aspect of the subject method, the thymidine phosphorylase is a conjugate which includes a targeting portion adapted to target the conjugate to a specific cell type or anatomical location. The thymidine phosphorylase has a thymidine phosphorylase activity of at least about 5%, preferably at least about 50% and, most preferably, at least about 90%, of the native E. coli enzyme.Type: GrantFiled: January 11, 1996Date of Patent: September 18, 2001Assignee: Delta Biotechnology Ltd.Inventors: David J. Ballance, Michael G. Courtney, Christopher J. A. Finnis, Darrell Sleep
-
Patent number: 5766883Abstract: A fusion polypeptide comprising, as at least part of the N-terminal portion thereof, an N-terminal portion of HSA or a variant thereof and, as at least part of the C-terminal portion thereof, another polypeptide except that, when the said N-terminal portion of HSA is the 1-n portion where n is 369 to 419 or a variant thereof then the said polypeptide is one of various specified entities.The HSA-like portion may have additional N-terminal residues, such as secretion leader sequences (signal sequences). The C-terminal portion is preferably the amino terminal fragment of human urokinase-type plasminogen activator. The N-terminal and C-terminal portions may be cleavable to yield the isolated C-terminal portion, with the N-terminal portion having served to facilitate secretion from the host. Such cleavage can be achieved in yeast using a sequence cleavable by the KEX2 protease of S. cerevisiae.Type: GrantFiled: November 17, 1993Date of Patent: June 16, 1998Assignee: Delta Biotechnology LimitedInventors: David J. Ballance, Andrew R. Goodey
-
Patent number: 5380712Abstract: Polypeptides corresponding to mature human serum albumin residues 1 to n, where n is between 369 and 419 inclusive, are useful as substitutes for albumin in the treatment of burns and shock in humans, the clearance of undesirable compounds, (such as bilirubin) from human blood, in laboratory growth media and in HSA assays. The polypeptides may be produced by recombinant DNA techniques, especially in yeast.Type: GrantFiled: February 14, 1992Date of Patent: January 10, 1995Assignee: Delta Biotechnology LimitedInventors: David J. Ballance, Edward Hinchliffe, Michael J. Geisow, Peter J. Senior